Mesodermal-Like Cells for Treatment Of Ischemia

Description:

Market: Peripheral artery disease affects 8-12 million Americans. Patients experience pain, numbness, and ulcers. Mobility can be affected, and gangrene can set in. It is estimated that there are 150,000 amputations each year in the United States is due to critical leg ischemia. Of those, the peri-operative mortality rate for below the knee amputations is 5-10%, with a 15-20% peri-operative mortality rate for above the knee amputations. In addition, it is estimated that 30% of first time amputees will require a second amputation. Further, patients with critical limb ischemia have an elevated risk of additional serious health issues, including myocardial infarction, stroke and vascular death. Alarmingly, 40% will die within two years. This critical public health issue demands a viable therapeutic.

Competitors and Current Problems: Currently, mild ischemia is often first treated with medication, exercise, and diet. For persistent or extreme cases, more invasive and aggressive procedures include bypass surgery, angioplasty, and stents. Stem cell therapy offers the possibility of rebuilding damaged and/or occluded tissues. Optimization of therapeutic cell population increases the likelihood of a successful outcome.

The Technology: Researchers at the University of Texas Health Science Center at Houston identified a specific subpopulation of bone marrow mononuclear cells, that differentiate into both blood vessels and skeletal muscle, in a mouse model of peripheral ischemia. The injected cells, without immunosuppressant therapy, were also associated with accelerated blood flow restoration and increased serum levels of VEGF, FGF-2, TGF-beta, IL-4, and TNF-alpha. In addition to ischemic patients, skeletal muscle formation offers potential benefit to patients suffering from skeletal muscle atrophy due to other causes.
 

References: Vasc Endovascular Surg. 2009 Oct-Nov;43(5):433-43. Epub 2009 Jul 23.

 

NON-CONFIDENTIAL TECHNOLOGY DESCRIPTION

The preceding is intended to be a non-confidential summary of a novel technology created at the University of Texas Health Science Center at Houston (UTHealth), for which the University is seeking patent protection.

UTHealth Ref. No.: 2008-0062

Inventors: Zoldhelyi, et al

Patent Status:  20110104124

License Available: world-wide; exclusive or non-exclusive

Patent Information:

The preceding is intended to be a non-confidential and limited description of a novel technology created at the University of Texas Health Science Center at Houston (UTHealth). This promotional material is not comprehensive in scope and should not replace company’s diligence in a thorough evaluation of the technology. Please contact the Office of Technology Management for more information regarding this technology.
Category(s):
Therapeutics
For Information, Contact:
University of Texas Health Science Center At Houston
 
Inventors:
Keywords:
© 2020. All Rights Reserved. Powered by Inteum